MYH9 and head and neck squamous cell carcinoma: The underlying mechanisms through which ACTN1 fosters HNSCC drug resistance and tumorigenesis encompass the activation of β-catenin via both MYH9-dependent GSK-3β degradation and intergrin β1-mediated FAK phosphorylation.